IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A pyrrolidine derivative of Formula I:



(I)

~~its~~ a geometrical ~~isomers~~ isomer thereof, ~~its~~ an optically active ~~forms~~ form thereof, ~~as enantiomers~~ an enantiomer thereof, ~~diastereomers~~ a diastereomer thereof, one or more mixtures thereof, ~~of these and its~~ a racemate ~~forms~~ form thereof, ~~as well as~~ or a salt ~~salts~~ thereof, wherein:

R^1 is selected from the group ~~comprising of~~ consisting of H and C_1-C_6-alkyl;

R^2 is selected from the group ~~comprising of~~ consisting of hydrogen, C_1-C_6-alkyl, C_1-C_6-alkyl aryl, heteroaryl, C_1-C_6-alkyl heteroaryl, C_2-C_6-alkenyl, C_2-C_6-alkenyl aryl, C_2-C_6-alkenyl heteroaryl, C_2-C_6-alkynyl, C_2-C_6-alkynyl aryl, C_2-C_6-alkynyl heteroaryl, C_3-C_8-cycloalkyl, heterocycloalkyl, C_1-C_6-alkyl cycloalkyl, C_1-C_6-alkyl heterocycloalkyl, C_1-C_6-alkyl carboxy, acyl, C_1-C_6-alkyl acyl, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl alkoxy, alkoxycarbonyl, C_1-C_6-alkyl alkoxycarbonyl, aminocarbonyl, C_1-C_6-alkyl aminocarbonyl, C_1-C_6-alkyl acylamino, C_1-C_6-alkyl ureido, amino, C_1-C_6-alkyl amino, sulfonyloxy, C_1-C_6-alkyl sulfonyloxy, sulfonyl, C_1-C_6-alkyl sulfonyl, sulfinyl, C_1-C_6-alkyl sulfinyl, C_1-C_6-alkyl sulfanyl, and C_1-C_6-alkyl sulfonylamino;

R^3 is selected from the group ~~comprising of~~ consisting of aryl and heteroaryl;

X is selected from the group consisting of O [[or]] and NR^4;

R^4 is selected from the group ~~comprising or~~ consisting of H, C_1-C_6-alkyl, C_1-C_6-alkyl aryl, C_1-C_6-alkyl heteroaryl, aryl and heteroaryl; [[or]] wherein

R^2 and R^4 can form together with the N atom to which they are linked to, a 5-8 membered saturated or unsaturated heterocycloalkyl ring; and

n is an integer from 1 to 3.

Claim 2 (Original): A pyrrolidine derivative according to claim 1, wherein R^1 is methyl.

Claim 3 (Currently Amended): A pyrrolidine derivative according to claim 1 ~~or 2~~, wherein R^3 is a phenyl.

Claim 4 (Currently Amended): A pyrrolidine derivative according to ~~any of the preceding claims~~ claim 1, wherein n is an integer 1 or 2.

Claim 5 (Currently Amended): A pyrrolidine derivative according to ~~any of the preceding claims~~ claim 1 wherein R^2 and R^4 form together with the N atom to which they are linked, a 5 or 6 membered cycloalkyl or heterocycloalkyl ring[[;]].

Claim 6 (Currently Amended): A pyrrolidine derivative according to ~~claims 1 to 4~~ claim 1 wherein X is O or NH.

Claim 7 (Currently Amended): A pyrrolidine derivative according to ~~any of the preceding claims~~ claim 1, selected from the ~~following~~ group consisting of:

(3EZ,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime;

(3EZ,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-(hydroxymethyl)pyrrolidin-3-one O-methyloxime;

(3E,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-(hydroxymethyl)pyrrolidin-3-one O-methyloxime;

(3Z,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-[(4-methylpiperazin-l-yl)methyl]pyrro-lidin-3-one O-methyloxime;

tert-butyl {[(2S,4EZ)-1-(1,1'-biphenyl-4-ylcarbonyl)-4-(methoxyimino)pyrrolidin-2-yl]methoxy}acetate;

{[(2S,4EZ)-1-(1,1'-biphenyl-4-ylcarbonyl)-4-(methoxyimino)pyrrolidin-2-yl]-methoxy}acetic acid;

2-{[(2S,4EZ)-1-(1,1'-biphenyl-4-ylcarbonyl)-4-(methoxyimino)pyrrolidin-2-yl]-methoxy}-N-(2-pyrrolidin-1-ylethyl)acetamide;

(3EZ,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-(methoxymethyl)pyrrolidin-3-one O-methyloxime;

(3EZ, 5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-[(4-methylpiperazin-1-yl)methyl]-pyrrolidin-3-one O-methyloxime;

(3EZ,5S)-l-(1,1'-biphenyl-4-ylcarbonyl)-5-{[(4-methoxyphenyl)amino]methyl}-pyrrolidin-3-one O-methyloxime;

(3EZ,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-({[2-(lH-pyrazol-1-yl)ethyl]amino)-methyl)-pyrrolidin-3-one O-methyloxime;

2-{[(2S,4EZ)-1-(l,1'-biphenyl-4-ylcarbonyl)-4-(methoxyimino)pyrrolidin-2-yl]-methyl}-1H-isoindole-1,3(2H)-dione;

(3EZ,5S)-5-(aminomethyl)-1-(1,1'-biphenyl-4-ylcarbonyl)pyrrolidin-3-one O-methyl-oxime;

N-{[(2S,4EZ)-1-(1,1'-biphenyl-4-ylcarbonyl)-4-(methoxyimino)pyrrolidin-2-yl]methyl}acetamide;

(3EZ,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-(piperidin-1-ylmethyl)pyrrolidin-3-one O-methyloxime; and

(3EZ,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-(2-hydroxyethyl)pyrrolidin-3-one O-methyloxime.

Claim 8 (Currently Amended): A ~~pyrrolidine according to any of the preceding claims for use as a~~ medicament comprising said pyrrolidine derivative according to claim 1.

Claim 9 (Currently Amended): ~~Use of a pyrrolidine derivative according to any of claims 1 to 7 as well as isomers, optically active forms as enantiomers, diastereomers and mixtures of these, as well as salts thereof for the preparation of a medicament for the prevention and/or treatment of~~ A method of treating preterm labor, premature birth or dysmenorrhea, said method comprising administering said pyrrolidine derivative according to claim 1 to a patient in need thereof in an amount sufficient to treat said preterm labor, said premature birth or said dysmenorrhea.

Claim 10 (Currently Amended). ~~Use of a pyrrolidine according to claim 1 to 7, for the preparation of~~ A method of preparing a medicament for the treatment of one or more disorders requiring the modulation of the oxytocin receptor, said method comprising incorporating said pyrolidine according to claim 1 in said medicament.

Claim 11 (Currently Amended): ~~Use according to claim 10, for the treatment or prevention of disorders~~ A method of treating a disorder associated with the oxytocin receptor activity, said method comprising administering said pyrrolidine derivative according to claim 1 to a patient in need thereof in an amount sufficient to treat said disorder.

Claim 12 (Currently Amended): ~~Use according to claim 10 or 11~~ The method according to claim 10, wherein said modulation consists in the blocking of the oxytocin receptor or in antagonising the binding of oxytocin to ~~its~~ said oxytocin receptor.

Claim 13 (Currently Amended): A pharmaceutical composition ~~containing a~~ comprising said pyrrolidine derivative according to ~~any of claims 1 to 7~~ claim 1 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 14 (Currently Amended): A process for the preparation of [[a]] said pyrrolidine derivative according to ~~any of claims 1 to 7,~~ claim 1 wherein X is O, comprising ~~the step of an O-alkylation of~~ O-alkylating an alcohol ~~derivatives~~ derivative of formula (II) with an alkylating agent R^2-LG wherein LG is a leaving group~~, with R^1, R^2, R^3 and n being as defined above.~~



II Ia II

to obtain said pyrrolidine derivative.

Claim 15 (Currently Amended): A process for the preparation of [[a]] said pyrrolidine derivative according to ~~any of claims 1 to 7~~ claim 1 wherein X is NR^4, comprising ~~the step of a~~ reductively aminating an aldehyde derivative of formula (XI) with an amine HNR^2R^4 ~~wherein R^1, R^2, R^3, R^4 and n are defined above.~~



XI Ib



XI

to obtain said pyrrolidine derivative.

Claim 16 (New): The method according to claim 11, wherein said oxytocin receptor activity consists in the blocking of the oxytocin receptor or in antagonising the binding of oxytocin to said oxytocin receptor.